Clinical trials: Kidney Transplant Infection
Hepatitis E
Seroprevalence of Hepatitis E in People With an Organ Transplant
Background: The hepatitis E virus causes an acute hepatitis that usually goes away by itself. Researchers in France studied people who received a liver or kidney transplant.
- Trial name
- NCT02190253
- Where
- 3 sites in United States
- Volunteers
- 447 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Transplant Immunosuppression
The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient
The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.
- Trial name
- NCT01424345
- Testing
- adjustment of immunosuppressant dosages, adjustment of the dosages of immunosuppressants
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- CAMC Health System
Renal Transplant Rejection, Renal Transplant Infection
NOMINATE/ Minimisation of Immunosuppression in Kidney Transplantation
Kidney transplantation provides the optimal form of kidney replacement therapy for the majority of people with end-stage kidney disease, and has now become the commonest form of kidney replacement therapy.
- Trial name
- NCT05073822
- Testing
- Tacrolimus
- Sponsor
- University College, London
Kidney Transplant Recipients, Liver Transplant Recipients
COVID Protection After Transplant-Immunosuppression Reduction
This study will enroll individuals who have: Completed primary series of mRNA COVID-19 vaccine, and An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine.
- Trial name
- CPAT-ISR (NCT05077254)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen
- Where
- 15 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.
Patients undergoing solid organ transplantation randomly selected from those who have received two doses of Spikevax (Moderna) vaccine, provided that a minimum of 8 weeks have elapsed from the second dose to the time of the start…
- Trial name
- REIN-TX (NCT05048940)
- Testing
- Janssen vaccine, Spikevax (Moderna) vaccine
- Where
- Spain
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Kidney Transplant, Pancreas Tranplant
Observational Study Concerning COVID-19 Infection in Transplanted Kidney, Pancreas or Pancreatic Islet Patients
Collect informations on the health status of transplanted patients (kidney, kidney / pancreas, pancreas or pancreatic islet) during the COVID-19 pandemic. All informations will be collected by short questionnaire via phone.
- Conditions
- Kidney Transplant, Pancreas Tranplant, Pancreatic Islet Transplantation
- Trial name
- NCT04377776
- Testing
- Practice details
- Where
- Italy
- Volunteers
- 644 people
- Sponsor
- IRCCS San Raffaele
Immunosuppression, Cancer
Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
Phase I/II Randomized Clinical Trial to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 hyperimmune serum. The study will include patients at early stage of COVID-19 with increased risk for severe disease due…
- Conditions
- Immunosuppression, Cancer, COVID-19, Other Complication of Kidney Transplant
- Trial name
- SOROCOV (NCT04834089)
- Testing
- AntiSARS-CoV-2 Serum
- Where
- 2 sites in Brazil
- Volunteers
- 618 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
DNA Virus Infection, Herpesviridae Infections
Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients
Study Phase: IV Study Type: Open-label, multicenter, randomised clinical trial with two arms stratified for an intensified immunosuppressive regimen in patients at high risk for acute rejection.
- Conditions
- DNA Virus Infection, Herpesviridae Infections, Cytomegalovirus Infection
- Trial name
- NCT00373165
- Testing
- Ganciclovir
- Volunteers
- 150 people
- Sponsor
- Lower Saxony Center for Nephrology
Asymptomatic Bacteriuria, Kidney Transplant Infection
Asymptomatic Bacteriuria in Early Kidney Transplantation Follow up
Urinary tract infection (UTI) continues to be the leading cause of infection and hospitalization in post-kidney transplant (RT) surveillance.
- Trial name
- NCT04333602
- Testing
- Urinary culture and treatment if asymptomatic bacteriuria is detected
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- Centenario Hospital Miguel Hidalgo
Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder
Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
The purpose of this study is to determine whether Fluzone High Dose increases the immune response to the influenza antigens contained in the vaccine compared to standard-dose Fluzone in immunocompromised children and young…
- Conditions
- Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV), Bone Marrow Transplant (BMT)
- Trial name
- NCT01685372
- Testing
- Fluzone High Dose, Fluzone
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver
Infection Due to Resistant Organism
FMT for MDRO Colonization After Infection in Renal Transplant Recipients
Transplant patients are at increased risk of colonization and infection with Multidrug Resistant Organisms (MDROs) due to medications that modify their immune systems, increased healthcare and antibiotic exposure, and surgical…
- Trial name
- PREMIX (NCT02922816)
- Testing
- Fecal Microbiota Transplant (FMT), Bowel preparation, Stool or perirectal swab sampling
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Kidney Transplant Recipients
Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients
The purpose of this study is to find out whether Varivax is safe for use in children with kidney transplants and whether it protects children from serious infection.
- Trial name
- NCT00005009
- Testing
- Varivax®
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Transplant Recipients
The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population
This study evaluates the safety and availability of oral valganciclovir(VGC) at the does of 450mg daily begin within 10 days after renal transplantation, and till to Day 100 posttransplant.
- Trial name
- NCT02973464
- Testing
- Valganciclovir, Ganciclovir
- Where
- China
- Volunteers
- 450 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Disorder Related to Transplantation, Virus Diseases
Replacement of Lamivudine by Telbivudine to Improve Renal Function
Nephrotoxicity is one of the adverse effects of lamivudine and dosage of lamivudine has to be reduced if patients' renal function is insufficiency. Telbivudine may improve glomerular filtration rate.
- Conditions
- Disorder Related to Transplantation, Virus Diseases, Injury Due to Exposure to External Cause
- Trial name
- NCT02447705
- Testing
- telbivudine
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Kidney Transplant Infection
Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.
Hypothesis: Valganciclovir prophylaxis can be discontinued before 3 months in CMV-seropositive renal transplant recipients receiving induction thymoglobulin when developing CMV-specific cellular immunity after transplantation.
- Trial name
- NCT03123627
- Testing
- New profilaxis, Profilaxis recommended
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Cancer
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
RATIONALE: Giving donor natural killer cells to patients who have undergone donor bone marrow transplant may make the transplant work better and keep cancer cells from coming back.
- Trial name
- NCT00569283
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Asan Medical Center
Opportunistic Infections
Validation of a Risk Score Opportunistic Infections Development in Kidney Transplant Patients
This study validate the usefulness of SIMPLICITY score to characterize the immune status of the kidney transplant receiver at two points along its course (the one and six months after transplantation), by determination in…
- Trial name
- SIMPLICITY (NCT03083756)
- Where
- 15 sites in Spain
- Volunteers
- 577 people
- Sponsor
- Sociedad Española de Trasplante
Transplantation Infection, Cytomegalovirus Infections
Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant
This is a 12-month single center, randomized, open-label, single center study designed to compare the safety and efficacy of everolimus and very low dose tacrolimus versus enteric-coated sodium mycophenolate and low tacrolimus…
- Trial name
- NCT02084446
- Testing
- Everolimus, Very Low Tacrolimus, Low Tacrolimus
- Where
- Brazil
- Volunteers
- 120 people
- Sponsor
- Ronaldo de Matos Esmeraldo, MD
Papillomavirus Infections
PApillomavirus in REnal Transplant Patient
The main goal of project is to study the distribution of HPV genotypes in the anogenital area and peripheral humoral immune responses HPV (total and neutralizing Ab) before and after renal transplantation.
- Trial name
- PATRE (NCT02845739)
- Testing
- Kidney transplanted patients
- Volunteers
- 58 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Cytomegalovirus Disease, Kidney Transplant Infection
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease…
- Trial name
- NCT02439957
- Testing
- Brincidofovir, Valganciclovir
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Jazz Pharmaceuticals